These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 39074568)
1. LncRNA PCIF1 promotes aerobic glycolysis in A549/DDP cells by competitively binding miR-326 to regulate PKM expression. Zhong W; Wang C; Sun Y Mol Cell Probes; 2024 Oct; 77():101977. PubMed ID: 39074568 [TBL] [Abstract][Full Text] [Related]
2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146 [TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway. Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643 [TBL] [Abstract][Full Text] [Related]
4. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis. Huang Q; Xing S; Peng A; Yu Z Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841 [TBL] [Abstract][Full Text] [Related]
5. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Liu B; Wang R; Liu H Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989 [TBL] [Abstract][Full Text] [Related]
6. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1. Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152 [TBL] [Abstract][Full Text] [Related]
7. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Wang L; Shang X; Feng Q Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109 [TBL] [Abstract][Full Text] [Related]
8. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway. Cai Y; Dong ZY; Wang JY Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323 [TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells. Tan D; Li G; Zhang P; Peng C; He B Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944 [TBL] [Abstract][Full Text] [Related]
10. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Ju ZS; Sun B; Bao D; Zhang XF Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788 [TBL] [Abstract][Full Text] [Related]
11. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway. Xiao XH; He SY Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431 [TBL] [Abstract][Full Text] [Related]
12. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2. He R; Liu H Gene; 2020 Jul; 747():144553. PubMed ID: 32165307 [TBL] [Abstract][Full Text] [Related]
13. DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p. Li C; Chen L; Song W; Peng B; Zhu J; Fang L Acta Histochem; 2021 Oct; 123(7):151788. PubMed ID: 34543777 [TBL] [Abstract][Full Text] [Related]
14. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network. Liu TT; Li R; Liu X; Zhou XJ; Huo C; Li JP; Qu YQ Int J Med Sci; 2021; 18(2):419-431. PubMed ID: 33390811 [No Abstract] [Full Text] [Related]
15. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7. Pan X; Chen Y; Shen Y; Tantai J Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576 [TBL] [Abstract][Full Text] [Related]
16. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498 [TBL] [Abstract][Full Text] [Related]
17. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp. Shen JG; Xu SN; Yin LG Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601 [TBL] [Abstract][Full Text] [Related]
18. Long-non-coding RNA AK001058: A genetic biomarker in cisplatin sensitivity of non-small-cell lung carcinoma. Deng Y; Li H; Liu C; Xia X; Lv Y; Zhang D; Liang J Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):217-220. PubMed ID: 38279432 [TBL] [Abstract][Full Text] [Related]
19. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
20. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]